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remain to be elucidated. Here, we demonstrated that TNF-a-induced expression of intercellular
adhesion molecule-1 (ICAM-1) was down-regulated by Lf in a DNA-binding dependent manner at
transcriptional level in endothelial cells. Our results showed that Lf bound to a DNA region in the
ICAM-1 promoter in vitro as well as in chromatin context. Lf inhibited binding of NF-jB to a prox-
imal NF-jB site in ICAM-1 promoter. This type of repression represents an additional mechanism for
the action of Lf in regulation of gene expression.
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Lactoferrin (Lf) is a multifunctional glycoprotein which is pres-
ent in breast milk [1–3] and also found in high concentration in
most exocrine secretions and in the secondary granules of neutro-
phils [4,5]. Lf was shown to exert a number of biological responses
such as primary defense against microbial infection, inﬂammation,
angiogenesis, and inhibition of tumor growth [6–10]. Regulation of
these processes by Lf is not understood clearly, although some of
these functions are thought to be independent of its ability to bind
ferric ions. Lf is known to be internalized and translocated into the
nucleus, where it may regulate expression of target genes [11–13].
Previous reports have documented that Lf and delta-Lf, an Lf iso-
form, regulate a number of genes via activation of signaling path-
ways or via binding to DNA [14–19].
Intercellular adhesion molecule-1 (ICAM-1) is a cell surface gly-
coprotein that plays important roles in cell adhesion and transen-
dothelial migration of leukocytes and Ag-speciﬁc activation of
T lymphocytes [20,21]. ICAM-1 is constitutively expressed in a
wide variety of cell types including leukocytes, endothelial and
epithelial cells [22]. ICAM-1 gene can be induced to high levels
by stimulation with external stimuli such as oxidative stresseschemical Societies. Published by Eand inﬂammatory cytokines. NF-jB activation has been shown to
play a predominant role in induction of ICAM-1 gene expression
by TNF-a and thrombin in endothelial cells [23,24]. In the present
study, we demonstrated that Lf repressed the expression of
TNF-a-induced ICAM-1 in endothelial cells at transcriptional level
and investigated the molecular mechanism responsible for its
inhibition.
2. Materials and methods
2.1. Cell culture
Human umbilical vascular endothelial cells (HUVECs) were
obtained from American Tissue Culture Collection and passages
5–8 were used. HUVECs were grown in M199 supplemented with
10% fetal bovine serum (FBS), 100 units/ml penicillin, 100 lg/ml
streptomycin, 3 ng/ml bFGF, and 5 units/ml heparin at 37 C under
a humidiﬁed 95% and 5% (v/v) mixture of air and CO2, respectively.
2.2. Plasmid constructions, transfection, and luciferase reporter assay
Different regions of 50-ﬂanking sequence were fused with pro-
moterless luciferase gene in pGL3-basic (Promega). The plasmid
pLf-T was constructed previously by inserting lactoferrin cDNA
into pRcCMV plasmid [16]. Multiple mutations were introduced
into the putative DNA elements within the pICAM-1(-1357)/Luclsevier B.V. All rights reserved.
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mutagenesis II kit (Stratagene). The mutagenic primers used in this
study are as follows: Mut1, forward 50-CCC GAT TGC TTT AGC TTG
Gcc ATT ggG GAG CTG AAG CGG CCA G-30 and reverse 50-CTG GCC
GCT TCA GCT CCc cAA Tgg CCA AGC TAA AGC AAT CGG G-30; Mut2,
forward 50-CCC GAT TGC TTT AGC TTG cAA gTT CCG GAG CTG AAG
CGG CCA G-30 and reverse 50-CTG GCC GCT TCA GCT CCG GAA cTT
gCA AGC TAA AGC AAT CGG G-30. Transfection was performed
according to the manufacturer’s protocol using Lipofectamine
2000 (Invitrogen). The cell extracts were prepared 24 h after trans-
fection for further analysis. The luciferase assays were performed
using the Luciferase Assay System (Promega).
2.3. Reverse transcription and real time polymerase chain reaction
Total RNA was isolated from HUVECs using a commercially
available RNA-Bee isolation kit (Tel-Test) as previously described
[10]. The following primers were used in PCR reactions: ICAM-1,
forward 50-CGA CCT TGG TTG TGG CTG ACT-30 and reverse 50-CCC
TTC TGG TTG GTG GCT TTG-30; b-actin, forward 50-ATC TGG CAC
CAC ACC TTC TA-30 and reverse 50-CGT CAT ACT CCT GCT TGC
TG-30. Real time PCRs were performed using the real-time ﬂuores-
cence detection method using the LightCycler System with a First-
Start DNA Master SYBR Green I kit (Roche Diagnostics). The primer
sequences for real-time PCR were as follows: ICAM-1, forward 50-
CTC CAA TGT GCC AGG CTT G-30 and reverse 50-CAG TGG GAA
AGT GCC ATC CT-30. GAPDH, forward 50-GTC TTC ACC ACC ATG
GAG AA-30 and reverse 50-AGG AGG CAT TGC TGA TGA TC-30. A neg-
ative control without cDNA template was performed to assess the
overall speciﬁcity.
2.4. Western blot analysis
Western blot analysis was performed using whole cell extracts
prepared from HUVECs, as previously described [10]. Cell extracts
were fractionated by electrophoresis on 10% SDS–PAGE gel and
transferred onto a nitrocellulose membrane. Nonspeciﬁc binding
was blocked by soaking the membrane in Tris buffered saline-
Tween 20 (TBS-T) buffer (50 mM Tris–HCl (pH 7.5), 150 mM NaCl,
and 0.1% Tween 20) containing 3% nonfat milk. The membrane was
incubated with polyclonal rabbit anti-human ICAM-1 (Santa Cruz).
Peroxidase activity on the membrane sheet was visualized on X-
ray ﬁlms by a standard enhanced chemiluminescence procedure.
2.5. Determination of ICAM-1 mRNA stability
Brieﬂy, 0–24 h after HUVEC cells were treatedwith orwithout Lf,
1 lg/ml of actinomycin D (Sigma)was then added to each culture to
stop the further synthesis of ICAM-1 transcript. HUVEC cells were
harvested from the cultures at the indicated time points following
the addition of actinomycin D, and total RNAwas isolated. The level
of ICAMmRNAwas quantiﬁed for each time point by semiquantita-
tive RT-PCR and a real-time RT-PCR as described above.
2.6. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared and EMSA were performed as
described previously with slight modiﬁcation [24]. The deoxyolig-
omers used for EMSAs were as follows: Wild type oligomer con-
taining NF-jB site of ICAM-1 promoter, 50-TTA GCT TGG AAA TTC
CGG AGC T-30; NF-jB mutant oligomer (Mut1) generating Lf bind-
ing site (LBS) with high afﬁnity (13), 50-TTA GCT TGG cAC TTg CAG
C T-30; NF-jB mutant oligomer (Mut2) with no LBS, 50-TTA GCT
TGG ccA TTg gGG AGC T-30. Oligomers were annealed and radiola-
beled by phosphorylation with [c-32P] ATP using T4 polynucleotide
kinase and puriﬁed on sodium Tris–EDTA (STE)-10 columns (BDBiosciences). The reaction products were separated on non-dena-
turing 6% polyacrylamide gels in 0.25X Tris–borated EDTA buffer.
After electrophoresis, the gels were dried and subjected to
autoradiography.
2.7. Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed to detect in vivo association of Lf and
NF-jB to ICAM-1 promoter according to the methods previously
described [25]. A portion of the lysate was saved for subsequent
puriﬁcation of input genomic DNA. The remaining supernatant
was pre-cleared with protein A Sepharose beads and sheared her-
ring sperm DNA, and followed by incubation with anti-lactoferrin
rabbit polyclonal antibody at 4 C overnight. The primers for
ampliﬁcation of NF-jB region were as follows: ICAM-1 forward
50-CGA TTG CTT TAG CTT GGA AA-30; ICAM-1 reverse 50-TTT ATA
GCG CTA GCC ACC TG-30. The primers for ampliﬁcation of random
sequence located upstream region of ICAM-1 promoter were also
used: forward 50-GCG TCT CTG GAT GGC CAG TG-30; reverse 50-
TCT TAA GTC TCC GAG CAC CA-30.
2.8. Avidin–biotin-complex DNA (ABCD) assay
ABCD assay was performed as described previously [25]. This
assay is based on the immobilization of protein–DNA complexes
via binding of a biotinylated oligonucleotide to a streptavidin.
200 ll HUVECs cell extract (5 mg/ml of protein concentration)
was incubated with 200 ll buffer H (100 mM KCl, 20 mM HEPES
pH 7.8–7.9, 20% glycerol, 1 mM DTT, 0.1% NP-40), 2 lg biotinylated
oligonucleotide, and Lf for 1 h on ice. After the addition of 40 ll
equilibrated streptavidin agarose beads (Amersham Pharmacia
Biotech), incubation was continued for 30 min at 4 C on a rotator.
Beads were washed repeatedly with buffer H (containing 50 mM
KCl), boiled in Laemmli sample buffer, and separated by SDS–PAGE
under reducing conditions. Enhanced chemiluminescence (Amer-
sham Pharmacia Biotech) was used for detection. Biotinylated oli-
gos ordered from Bioneer (Seoul, Korea) comprise the following
sequences: wild type, 50-TTA GCT TGG AAA TTC CGG AGC T-30;
Mut1(high afﬁnity LBS), 50-TTA GCT TGG CAC TTG CGG AGC T-30;
Mut2(no LBS), 50-TTA GCT TGc AAg TTC CGG AGC T-30.
2.9. Confocal laser scanning microscope for translocation of Lf
To observe the fate of Lf added to living cells, Lf (25 lg/ml) was
conjugated to FITC (PIERCE) for 1 h in PBS and dialyzed against PBS
according to manufacturer’s instruction. HUVECs were incubated
with FITC-labeled Lf for 12 h, ﬁxed with 3.7% paraformaldehyde,
and then washed in PBS. To examine the distribution of Lf, the ﬁxed
cells were mounted with mounting solution containing DAPI (40-6-
diamidino-2-phenylindole), and photographed using a laser-scan-
ning confocal microscope (Carl Zeiss).2.10. Statistical analysis
The data are presented as means ± SD and statistical compari-
sons between groups were performed by Student’s t-test.3. Results
3.1. Human Lf down-regulates TNF-a-induced expression of ICAM-1
To examine whether Lf regulates expression of TNF-a-induced
ICAM-1, HUVECs were pretreated without or with various concen-
trations of Lf for 12 h and then stimulated with TNF-a for 12 h.
TNF-a-induced ICAM-1 gene expression was signiﬁcantly
Fig. 1. Down-regulation of TNF-a-induced ICAM-1 expression in endothelial cells by Lf. (A) HUVECs were pretreated with various concentrations of Lf for 12 h and then
stimulated with TNF-a (2 ng/ml) for 12 h. ICAM-1 mRNA levels were measured by RT-PCR analysis using speciﬁc primers. b-Actin mRNA was used as control. (B) ICAM-1
protein levels were measured by Western blot analysis using anti-ICAM-1 antibody. b-Actin protein was used as control. (C) HUVECs were transfected with various
concentrations of pLf for 4 h and then stimulated with TNF-a (2 ng/ml) for 12 h. ICAM-1 mRNA levels were measured by RT-PCR analysis using speciﬁc speciﬁc
oligonucleotide primers for ICAM-1. (D) ICAM-1 protein levels were measured by Western blot analysis using anti-ICAM-1 antibody. (E) ICAM-1 expression levels were
detected by ﬂuorescence microscopy using anti ICAM-1-FITC. (F) ICAM-1 proteins were measured by cell based ELISA using ICAM-1 antibody. ⁄⁄P < 0.05 versus TNF-a alone.
The data are mean values ± SD from quadruplicates and are representative of at least three experiments.
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(Fig. 1A). The decreased expression of ICAM-1 protein was shown
by Western blot analysis in TNF-a-stimulated endothelial cells
after treatment with Lf (Fig. 1B). Our data showed that ICAM-1
expression was not affected by treatment with Lf alone in HUVECs.
We next investigated whether the endogenously expressed Lf
could inhibit the expression of TNF-a-induced expression of
ICAM-1. HUVECs were transfected with various amounts of pLf-T
for 4 h and then stimulated with TNF-a. The levels of TNF-a-
induced ICAM-1 mRNAs were reduced in dose-dependent manner
in HUVECs expressing Lf (Fig. 1C). The ICAM-1 protein levels were
similarly decreased in the transfected endothelial cells, as demon-
strated by Western blot analysis (Fig. 1D), ﬂuorescent staining of
cells using FITC-labeled anti-ICAM-1 (Fig. 1E) and cell-based ELISA
(Fig. 1F).
3.2. Lf inhibits TNF-a-induced ICAM-1 expression at transcriptional
level
We analyzed whether Lf regulates ICAM-1 gene expression at
the transcriptional level using ICAM-1/luciferase reporter gene
constructs. High levels of induction with TNF-a were observed
with the reporter constructs containing the 50-ﬂanking sequence
up to 468 bp from the transcription initiation site and the in-
duced ICAM-1 promoter activities were inhibited in Lf-treated cells
signiﬁcantly (Fig. 2A). The 50-deletion up to 112 resulted in a
complete loss of TNF-a-induced promoter activity. The promoter
region contains a NF-jB binding sequence, 50-GGAAATTCC-30 at
the position 187 to 178 from the transcription initiation site
of ICAM-1 gene, which is known to play a critical role in TNF-a-in-
duced activation of ICAM-1 gene expression [26,27]. Sequencecomparison of Lf binding sequences to the ICAM-1 promoter region
revealed that the sequence GGAAATTCC at the position 187 to
178 in ICAM-1 promoter was found in be very similar to
GGCACTTGC, one of Lf binding sequences previously reported
[13], indicating that Lf may bind to the proximal NF-jB site. We
constructed wild type promoter construct, pICAM-1(-1357)/Luc
and also two different NF-jB mutations in pICAM-1(-1357)/Luc,
and analyzed transcription in HUVECs. Our results showed that
mutation of NF-jB site to GGccATTgg (Mut2) abolished induction
of ICAM-1 promoter activity by TNF-a (Fig 2A). In contrast, muta-
tion of NF-jB site to Mut1 with high afﬁnity LBS retained low level
of inducibility of ICAM-1 promoter by TNF-a, which was strongly
inhibited by treatment with Lf.
We examined whether Lf affects ICAM-1 mRNA stability. Acti-
nomycin D inhibition assays showed that the half-lives of ICAM-
1 mRNA appeared to be similar between mock- and Lf-treated cells
as shown by RT-PCR (Fig. 2B upper) and by quantitative real-time
PCR (Fig. 2B lower). The results suggest that a stability mechanism
appeared not to be responsible for the decrease in ICAM-1 expres-
sion by Lf.
3.3. Lf binds to a DNA region in ICAM-1 promoter
Electromobility shift assays showed that puriﬁed Lfwas bound to
aDNA fragment containing theproximalNF-jB site of human ICAM-
1 promoter (Fig. 3A). Speciﬁc binding of Lf to the ICAM-1 promoter
probe was demonstrated by competition with an excess of unla-
beled probe and by supershift assay using an antibody against hu-
man Lf. The LBS (Mut1) with high afﬁnity for Lf competed more
efﬁciently than wild type ICAM-1 oligomer. Competition with
Mut2 oligomer did not affect the formation of the Lf-DNA complex
Fig. 2. Inhibition of TNF-a-induced expression by Lf at transcriptional level. (A)
Analysis of ICAM-1 promoter/Luc expression in endothelial cells. Various ICAM-1
promoter fragments and ICAM-1 promoter containing Mut1 or Mut2 sequence in
the proximal NF-jB site were fused to luciferase reporter gene. The plasmids were
transfected into HUVEC using Lipofectamine. After transfection, cells were treated
with Lf (20 lg/ml) for 12 h, and stimulated with TNF-a (2 ng/ml) for 12 h. Cell
extracts were analyzed for luciferase activities using luminometer. Values are the
average of three separate experiments in triplicate samples. RLU: relative
luminescence unit. (B) ICAM-1 mRNA levels in the absence or presence of Lf.
HUVECs were preincubated for 12 h in the absence or presence of Lf (50 lg/ml) and
stimulated with TNF-a (2 ng/ml). Actinomycin D (1 lg/ml) was then added and
total cellular RNA was harvested at the indicated time points (0–24 h). RT-PCR (top
panel) or a real-time RT-PCR (lower panel) were performed. Results are means of
three different experiments.
Fig. 3. Lf binds to ICAM-1 promoter region and nuclear translocation of Lf in
HUVECs. (A) Human Lf (Sigma) was incubated with 32P-end-labeled oligonucleo-
tides in the absence or presence of excess of unlabeled competitors. Mut
competitors are DNA fragments as shown in Fig. 2A. Supershift experiments were
performed using antibody against Lf. (B) The nuclear translocation of Lf in HUVECs.
HUVECs were incubated with 25 lg/ml FITC-conjugated Lf for 12 h and ﬁxed with
paraformaldehyde. The ﬁxed cells were mounted with mounting solution contain-
ing DAPI and photographed using a laser-scanning confocal microscope. The
nucleus is represented by the blue color in left panel, Lf represented by the green
color in middle panel, and the merged image is shown in right panel. (C) ChIP assays
were performed in HUVECs pre-treated with Lf for 12 h and/or treated with TNF-a
for 2 h as indicated on the left of the Fig 3C. Antibodies used for precipitation are
shown on the top. The DNA region comprising the proximal NF-jB site or upstream
non-speciﬁc region was ampliﬁed by PCR using speciﬁc primers. Input represents
PCR ampliﬁcation of the unprecipitated DNA.
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fragment containing the NF-jB site of ICAM-1 promoter.
We determined that exogenous Lf could be internalized and
translocated into the nucleus, using confocal laser microscopic
analysis of HUVECs treated with FITC-labeled Lf. The co-labeling
of HUVECs showed that the nucleus (blue color, Fig. 3B, left) and
FITC-labeled Lf (green color, Fig. 3B, middle) appear to be colocal-
ized. The merged image (Fig. 3B, right), obtained by overlaying two
images from Fig. 3B (left, middle), demonstrates that Lf is localized
inside the nucleus of the endothelial cells.
DNA binding analysis in vivo by ChIP showed that NF-jB was
bound to the proximal region of ICAM-1 promoter in endothelial
cells treated with TNF-a. Pretreatment of cells with Lf resulted in
reduction of p50 and p65 subunits of NF-jB binding as well as in
substantial binding of Lf to the region, indicating that Lf binds to
ICAM-1 promoter in vivo (Fig. 3C). Lf did not bind to an upstream
non-speciﬁc region of ICAM-1 promoter, indicating that binding ofLf to the proximal site is speciﬁc. The results suggest that Lf may
down-regulate transcription of ICAM-1 gene via competition of
binding to ICAM-1 promoter of speciﬁc LBS with NF-jB.
3.4. Lf inhibits binding of NF-jB to the ICAM-1 promoter
Wefurther investigatedwhether treatmentofHUVECswith Lf af-
fects TNF-a-stimulatedNF-jB binding to the proximal NF-jB site in
the ICAM-1 promoter. DNA binding activities of proteins in nuclear
extractsofHUVECs incubated in thepresence Lfwereanalyzedusing
32P-labelled oligonucleotides corresponding to the NF-jB binding
site (Fig. 4A). Formation of NF-jB-DNA complexes was prominent
in nuclear extracts from TNF-a-stimulated cells. When HUVECs
were treated with Lf at 12.5 lg/ml and stimulated with TNF-a, a
band of NF-jB-DNA complexes was reduced slightly comparing to
only TNF-a treated endothelial cells, although we were not able to
Fig. 4. Lf reduces binding of NF-jB to the proximal NF-jB site of ICAM-1 promoter.
(A) 50 lg of nuclear extracts were incubated on ice for 30 min with 32P-end-labeled
oligonucleotides in a binding buffer containing 3 lg of poly(dI–dC) in the absence
or presence of excess of unlabeled competitors. One microgram of puriﬁed Lf (pLf)
was incubated under the same condition as a positive control. Supershift exper-
iments were performed by preincubating nuclear extracts with 1 lg of antibody
against p65 or p50. Upper arrows indicates NF-jB/DNA complexes and lower
arrows indicate the position of Lf/DNA complexes. Mut1 and Mut2 are described in
Fig. 2A. (B) Effects of Lf on TNF-a-induced phosphorylation of IjB-a and nuclear
translocation of NF-jB. HUVECs were pre-treated with Lf at 50 lg/ml concentration
at the indicated time and then treated with TNF-a (2 ng/ml) for 2 h. Cell lysates
were analyzed by Western blot analysis using speciﬁc antibodies against IjB-a or
phosphorylated IjB-a. Nuclear extracts were prepared and analyzed by Western
blot analysis using speciﬁc antibody against p65 subunit of NF-jB. PCNA was used
as control. (C) Binding of Lf to a DNA region containing the proximal NF-jB was
shown by avidin–biotin-complex DNA (ABCD) assay. Biotinylated oligonucleotides
of containing the proximal NF-jB in ICAM-1 promoter were used in an ABCD assay
with TNF-a induced HUVECs lysates. Oligomers of wild type ICAM-1 promoter
region containing the proximal NF-jB, consensus LBS [13], Mut2 and scrambed
oligomer (SCRBL) were used as probe (upper panel). The sequences of the oligomers
are shown in Fig. 2A. Addition of non-biotinylated oligonucleotides in large excess
of molar ratios reduced binding of Lf as well as NF-jB to wild type oligomer (middle
panel). Addition of increasing amounts of Lf to the wild type oligomer attenuated
NF-jB binding to NF-jB site in ICAM-1 promoter (lower panel).
C.W. Kim et al. / FEBS Letters 586 (2012) 229–234 233see appearance of a band of Lf-DNA complexes. However, whenHU-
VECs were treated with Lf at 50 lg/ml and stimulated with TNF-a,
NF-jB-DNA complexes diminished and Lf-DNA complexes were
formed instead, which was migrated to the same position as those
of puriﬁed Lf-DNA complexes on the gel. Cold wild type (WT) oligo-
mer at 50molar excess inhibited formation of Lf-DNA complexesrather weakly (Data not shown). WT oligomer at 200 and the
Mut1 (mutated to Lf consensus sequence) oligomer at 50 excess
inhibited the formation of Lf-DNA complexes completely, indicating
that the Mut1 competed more efﬁciently than WT oligomer for
Lf-DNA complexes, which is consistent with the result observed in
Fig. 3A. Mut2 (mutated to random sequence) oligomer did not inhi-
bit formation of Lf-DNA complexes. The antibody of Lf inhibited for-
mation of the complexes, while antibodies directed against p65 or
p50 subunit of NF-jB did not inhibit formation of Lf-DNA com-
plexes. Inhibition of NF-jB binding by Lf was not due to reduction
of nuclear translocation of NF-jB, because Lf alone did not affect
phosphorylation of IjB-a and nuclear translocation of NF-jB
(Fig. 4B). TNF-a-activated phosphorylation of IjB-a was not chan-
ged by Lf up to 24 h. Our results demonstrate that Lf inhibits binding
of NF-jB to the site in ICAM-1 promoter via competition for the
overlapped site.
ABCD assays demonstrated that Lf bound to the DNA region
containing the proximal NF-jB site in ICAM-1 promoter and to
LBS sequence (Mut1). However, Lf did not bind to the Mut2
sequence used in Fig. 2A or to the scrambled sequence. When
non-biotinylated competitor DNA was added to the assays, the
competitor attenuated not only Lf binding but also NF-jB binding
to the DNA fragment (Fig. 4B middle panel). Addition of increasing
amounts of Lf attenuated NF-jB binding to the DNA region in the
ICAM-1 promoter (Fig. 4B lower panel). Our results suggest that
Lf inhibited binding of NF-jB to the proximal binding site.4. Discussion
The present study aimed at investigating effects of Lf on ICAM-1
gene expression and the underlying mechanism of gene regulation
by human Lf in endothelial cells. Our results showed that the inhib-
itory effect of Lf on TNF-a-induced ICAM-1 mRNA steady state lev-
els in cells was primarily due to inhibition of transcription of the
ICAM-1 gene, rather than promoting degradation of ICAM-1 mRNA.
Inhibition of TNF-a-induced ICAM-1 expression in endothelial cells
by Lf was DNA binding-dependent. It has been reported that TNF-
a-induced activation of ICAM-1 gene expression is primarily regu-
lated through NF-jB activation [27], which mediates a wide range
of transcriptional responses, including IL-1b, thrombin and LPS re-
sponses [22]. Analysis of ICAM-1 promoter showed that the region
upstream of the proximal NF-jB site is not functionally important
for NF-jB activation as well as Lf-responsiveness.
Sequence comparison of the ICAM-1 promoter region revealed that
thesequenceGGAAATTCCat theposition187 to178 in ICAM-1pro-
moter was found in be very similar to GGCACTTGC, one of Lf binding
sequences. Indeed, we showed that Lf is able to bind directly to the re-
gion containing the proximal NF-jB site in vitro and in vivo.We found
that pretreatment of cells with Lf inhibited binding of TNF-a-stimu-
lated NF-jB binding to the ICAM-1 promoter by EMSA and ABCD as-
says. ChIP assay demonstrated that Lf also reduced TNF-a-stimulated
NF-jB binding to its promoter elements in vivo.
The present results demonstrated that exogenous Lf was trans-
located into nucleus of endothelial cells by confocal laser scanning
microscopic analysis of FITC-conjugated Lf, where Lf was detected
in the nucleus within 1 h of administration. Other investigators
previously reported that exogenous Lf was transported to the nu-
cleus of the cells such as human K562 and Caco-2 cells [11,12].
Other investigators reported that upstream components of NF-
jB, TNFR-associated factors, IKKb, NIK or MEKK1 participated in
NF-jB activation by Lf signaling [15,28]. However, our results
showed that Lf alone did not activate phosphorylation of IjB, and
thereby phosphorylation of IjB and translocation of NF-jB in TNF-
a-activated endothelial cells was not increased any further by pre-
treatment with Lf. The discrepancy may be explained by different
234 C.W. Kim et al. / FEBS Letters 586 (2012) 229–234cell types or by differences of Lf concentrations used for the studies.
Transfection of endothelial cells with plasmid expressing human Lf
showed that endogenously expressed Lf was able to inhibit TNF-a-
stimulated ICAM-1 expression, suggesting that Lf may not require
signaling pathways of NF-jB for inhibition of ICAM-1 expression
by Lf in endothelial cells.
Up-regulation of adhesion molecules on the surface of the endo-
thelium plays a key role in recruitment and inﬁltration of polymor-
phonuclear leukocyte (PMN) at inﬂammation sites. We observed
that U937 monocytoid cell adhesion to endothelial cells was re-
duced signiﬁcantly by Lf (data not shown), which was reported
by other group recently [29]. Serum Lf are primarily released from
secondary granules of neutrophils and circulate at concentrations
of 0.1–3 lg/ml in healthy adults and the local concentrations of
Lf tend to be far higher in inﬂammatory regions [30]. Our results
showed that Lf, at concentration encountered at the inﬂammatory
site, strongly inhibits TNF-a-stimulated expression of ICAM-1 via
competing with NF-jB in endothelial cells. Taken together, our re-
sults suggest one of underlying mechanisms by which Lf reduces
inﬂammatory events and development of inﬂammatory diseases
such as atherosclerosis.
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